European Archives - Page 522 of 1199 - European Medical Journal

Implications of Elevated Postprandial Glucose and Nutritional Approaches for Postprandial Glucose Management with a Focus on Whey Proteins

This symposium took place at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden. The first speaker was John L. Sievenpiper, who discussed the pathophysiology of postprandial hyperglycaemia and how it may impact the risk of cardiovascular disease (CVD), peripheral vascular disease, insulin resistance, and other comorbidities in patients with Type 2 diabetes (T2D).

Tropical Diabetic Hand Syndrome: A Case Report and Literature Review

TDHS is characterised by symptoms ranging from a localised cellulitis to gangrene and sepsis. This article reports on the importance of timely intervention and patient education.

Adapting to Telemedicine in Diabetes

THIS year’s European Association for the Study of Diabetes (EASD) Annual Meeting 2022 was a hybrid congress, which focused on inclusion and interaction within the global diabetes community whether participants attended in person in Stockholm, Sweden, or virtually.

Could the UK become a medicinal cannabis leader?

A new review has outlined 20 recommendations for how the UK can become a world leader in cannabinoid innovation. But is it possible?

Pfizer joins GSK in RSV success

Pfizer plans to file for approval for its RSV vaccine for infants by the end of 2022 after achieving positive Phase 3 results.

Pharma insights from the team behind GOLD

Listen to the GOLD team: Helena, Isabel and Jade will discuss key articles, themes and insights from the latest issue of GOLD.

How is pharma improving animal testing – and what do activists think?

The pharmaceutical industry has been trying to refine, reduce and replace animal testing for some time, but animal rights activists argue progress is too incremental.

Pharma's response to Roe v. Wade

The overturning of Roe v. Wade is impacting access to medical abortion, but in what ways is pharma trying to help?

Retracted: Building on a Strong Foundation to Address a New Era to Help Protect Against Pneumococcal Disease

Ramirez noted that more than 100 pneumococcal serotypes have now been identified, which is most likely the result of increased…

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older

Learn about NUVAXOVIDᵀᴹ dispersion for injection COVID-19 vaccine (recombinant, adjuvanted) for individuals 12 Years and older.